医学
放射治疗
胰腺癌
肿瘤科
新辅助治疗
化疗
癌症
内科学
全身疗法
疾病
临床试验
乳腺癌
作者
Kevin M. Turner,Aaron M. Delman,Jordan Kharofa,Milton T. Smith,Kyuran A. Choe,Olugbenga Olowokure,Gregory C. Wilson,Sameer H. Patel,Davendra Sohal,Syed A. Ahmad
出处
期刊:Surgery
[Elsevier]
日期:2022-07-01
卷期号:172 (1): 284-290
被引量:3
标识
DOI:10.1016/j.surg.2021.12.013
摘要
Background Borderline resectable pancreatic cancer constitutes a complex clinical entity, presenting the clinician with a locally aggressive disease that has a proclivity for distant spread. The benefits of radiation therapy, such as improved local control and improved survival, have been questioned. In this review we seek to summarize the existing evidence on radiation therapy in borderline resectable pancreatic cancer and highlight future areas of research. Methods A comprehensive review of PubMed for clinical studies reporting outcomes in borderline resectable pancreatic cancer was performed in June 2021, with an emphasis placed on prospective studies. Results Radiologic “downstaging” in borderline resectable pancreatic cancer is a rare event, although some evidence shows increased clinical response to neoadjuvant chemotherapy over radiation therapy. Margin status seems to be equivalent between regimens that use neoadjuvant chemotherapy alone and regimens that include neoadjuvant radiation therapy. Local control in borderline resectable pancreatic cancer is likely improved with radiation therapy; however, the benefit of improved local control in a disease marked by systemic failure has been questioned. Although some studies have shown improved survival with radiation therapy, differences in the delivery and tolerance of chemotherapy between the neoadjuvant and adjuvant setting confound these results. When the evidence is evaluated as a whole, there is no clear survival benefit of radiation therapy in borderline resectable pancreatic cancer. Conclusion Once considered a staple of therapy, the role of radiation therapy in borderline resectable pancreatic cancer is evolving as systemic therapy regimens continues to improve. Increased clinical understanding of disease phenotype and response are needed to accurately tailor therapy for individual patients and to improve outcomes in this complex patient population.
科研通智能强力驱动
Strongly Powered by AbleSci AI